Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m 6 A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Badia, Roger|||0000-0003-3982-7577
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Revilla, Lluís
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Roca, Núria
  • Ceada, Gerardo|||0000-0002-0524-4018
  • Kochanowski, Karl|||0000-0002-1884-7694
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Boreika, Rytis|||0000-0001-6720-1577
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Soler, Laia|||0009-0000-4122-5079
  • Guil, Sonia|||0000-0002-2257-3331
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Paredes, Roger|||0000-0002-6553-691X
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m 6 A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m 6 A synthesis routes and are blocked by drugs targeting IGF2BP2 m 6 A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses. By deciphering the molecular fingerprint of cells treated with host-directed therapies targeting protein translation, the authors identified a rational approach to select for broad-spectrum antivirals with potential to counteract future pandemic viruses.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta
  • Du, Juan
  • Wortmann, Diana D. J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza
  • Arrieta Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier
  • Grau Cerrato, Santiago
  • Garcia Giralt, Natàlia
  • Perez-Zsolt, Daniel
  • Boreika, Rytis
  • Izquierdo-Useros, Nuria
  • Güerri Fernández, Roberto
  • Meyerhans, Andreas
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations., This work received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), Centro de Investigación Biomédica en Red Enfermedades Infecciosas, CIBERINFEC (CB21/13/00002), FEDER funds, FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, the Spanish Ministry of Science and Innovation grant number PID2022-141395OB-I00, and the “Unidad de Excelencia María de Maeztu,” funded by the MCIN and the AEI (DOI: 10.13039/501100011033). Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain

  • Agustí Benito, Cristina
  • Adell Lorente, Héctor
  • Casabona, Jordi
The recent monkeypox virus (MPXV) outbreak was of global concern and has mainly affected gay, bisexual and other men who have sex with men (GBMSM). Here we assess prevalence of MPXV in high-risk populations of GBMSM, trans women (TW) and non-binary people without symptoms or with unrecognized monkeypox (Mpox) symptoms, using a self-sampling strategy. Anal and pharyngeal swabs are tested by MPXV real-time PCR and positive samples are tested for cytopathic effect (CPE) in cell culture. 113 individuals participated in the study, 89 (78.76%) were cis men, 17 (15.04%) were TW. The median age was 35.0 years (IQR: 30.0–43.0), 96 (85.02%) individuals were gay or bisexual and 72 (63.72%) were migrants. Seven participants were MPXV positive (6.19% (95% CI: 1.75%–10.64%)). Five tested positive in pharyngeal swabs, one in anal swab and one in both. Six did not present symptoms recognized as MPXV infection. Three samples were positive for CPE, and showed anti-vaccinia pAb staining by FACS and confocal microscopy. This suggests that unrecognized Mpox cases can shed infectious virus. Restricting testing to individuals reporting Mpox symptoms may not be sufficient to contain outbreaks., The authors acknowledge the collaboration of Gema Ballega, Pili Bonamusa, Pamela Nef, Ana Isabel Parra Manzano, Enola Crespillo, Aroa Muñoz, Núria Vaquero, Elisa Molina Molina and F. Hoffmann-La Roche Ltd. In addition, the authors thank Harvey Evans for the English revision. This work was supported by the Ministry of Health of Government of Catalonia (Spain) [no grant number] and Hoffmann-La Roche Laboratories. NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding from Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. Finally, the authors thank the CERCA Programme/Generalitat de Catalunya for their support of the Germans Trias i Pujol Research Institute (IGTP).
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • de Homdedeu, Miquel
  • Sanchez-Moral, Lidia
  • Violán, Concepció
  • Ràfols, Neus
  • Ouchi, Dan
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodríguez-Cortés, Alhelí
  • Arch-Sisquella, Marta
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Izquierdo-Useros, Nuria
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi
  • Segalés, Joaquim
  • Vilaplana, Cristina
  • Torán-Monserrat, Pere
  • Morros, Rosa
  • Monfà, Ramon
  • Sarrias, Maria-Rosa
  • Cardona, Pere-Joan
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days., The MANRECOVID19 clinical trial has been sponsored by the Reig Jofre Group. This research was funded by the Consorcio Centro de Investigación Biomédica en Red (CIBERES and CIBEREHD) and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847762. MDH is supported by a Margarita Salas grant from NextGenerationEU. LS-M is supported by Juan de la Cierva fellowship (FJC2019-041213-I). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118), and institutional funding from Grifols, Pharma Mar, HIPRA, Amassence, and Palobiofarma. The Innate Immunity lab and the UTE are accredited by the Catalan Agency for Management of University and Research Grants (2017-SGR-490/2021-SGR-01186, 2021-SGR-00931, and 2017-SGR-500/2021 SGR 00920). IGTP is a member of the CERCA network of institutes supported by the Health Department of the Government of Catalonia., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dalia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Tarrés Freixas, Ferran
  • Sachse, Martin
  • Perez-Zsol, Daniel
  • Muñoz Basagoiti, Jordana
  • Fernández-Sánchez, Sara Y.
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Nuñez-Delicado, Estrella
  • Casas, Josefina
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mónica
  • Usai, Carla
  • Lorca-Oró, Cristina
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet Sala, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals

  • Usai, Carla
  • Pailler García, Lola
  • Lorca-Oró, Cristina
  • Fernández-Bastit, Leira
  • Roca, Núria
  • Brustolin, Marco
  • Rodon Aldrufeu, Jordi
  • Pérez, Mónica
  • Cantero Portillo, Guillermo
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Clotet, Bonaventura
  • Napp, Sebastian
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
Rodents are widely used for the development of COVID-19-like animal models, the virological outcome being determined through several laboratory methods reported in the literature. Our objective was to assess the agreement between methods performed on different sample types from 342 rodents experimentally infected with SARS-CoV-2 (289 golden Syrian hamsters and 53 K18-hACE2 mice). Our results showed moderate agreement between methods detecting active viral replication, and that increasing viral loads determined by either RT-qPCR or infectious viral titration corresponded to increasing immunohistochemical scores. The percentage of agreement between methods decreased over experimental time points, and we observed poor agreement between RT-qPCR results and viral titration from oropharyngeal swabs. In conclusion, RT-qPCR and viral titration on tissue homogenates are the most reliable techniques to determine the presence and replication of SARS-CoV-2 in the early and peak phases of infection, and immunohistochemistry is valuable to evaluate viral distribution patterns in the infected tissues., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species

  • Tarrés Freixas, Ferran
  • Ceada, Gerardo
  • Català-Moll, Francesc
  • Casadellà, Maria
  • Tolosa-Alarcón, Sara
  • Franco-Trepat, Eloi
  • Boreika, Rytis
  • Almagro-Delgado, Vanessa
  • Carmona, Noelia
  • Estruch, Josep
  • Fernández-Bellon, Hugo
  • Fuentes-Moyano, Laura
  • Molina-López, Rafael
  • Navarro, Nuria
  • Parera, Mariona
  • Pérez Simó, Marta
  • Repullés, Joan
  • Roca, Núria
  • Torne, Odalys
  • Velarde, Roser
  • Valencia, Alfonso
  • Paredes, Roger
  • Izquierdo-Useros, Nuria
  • Romero-Durana, Miguel
  • Kochanowski, Karl
  • Vergara-Alert, Júlia
Identifying animal species that are susceptible to the plethora of existing and emerging viruses is critical for predicting and containing disease outbreaks. Current efforts to assess viral tropism largely rely on experimental infection models, but such experiments are logistically and ethically infeasible for many wildlife species. To tackle this challenge, we developed a panel of airway organoids from ten taxonomically diverse wildlife and livestock species and evaluated their susceptibility to influenza viruses of mammalian (pH1N1) and avian (H5N1) origin. Our analyses revealed large host-specific differences in infection rate and cytopathogenicity that aligned with known in vivo data and field observations. Furthermore, we demonstrated that this organoid panel can serve as a powerful tool to elucidate receptor-binding mechanisms, viral dynamics and early host adaptation in poorly characterized animal hosts. In summary, this work provides a robust and ethically viable approach for evaluating viral tropism and adaptation in wildlife species, and may aid current pandemic preparedness, zoonotic disease surveillance and wildlife conservation efforts., This project was supported by a “Proyectos en lineas estratégicas” grant from the Spanish Ministry of Research and Innovation (project ID: PLEC2022-009171 /AEI/10.13039/501100011033). KK acknowledges additional support by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033). N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 /AEI/10.13039/501100011033), EU HORIZON-HLTH-2021 CORONA-01 (grant 101046118), EU HORIZON-HLTH-2023-DISEASE-03, and by institutional funding from PharmaMar, HIPRA, Amassence and Smart Vitamins. NIU is part of PTI-CSIC Salud Global. The authors also thank the support of CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023050389-I. MRD was supported by a fellowship within the “Generación D” initiative, Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by the European Union NextGenerationEU funds through PRTR. The authors also acknowledge the crowdfunding initiative #Yomecorono, available online at https://www.yomecorono.com., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna
  • Tarrés Freixas, Ferran
  • Pérez Maíllo, Mónica
  • Riveira-Muñoz, Eva
  • Raïch-Regué, Dàlia
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Tondelli, Barbara
  • Pradenas, Edwards
  • Izquierdo-Useros, Nuria
  • Capdevila, Sara
  • Vergara-Alert, Júlia
  • Urrea, Victor
  • Carrillo, Jorge
  • Ballana, Ester
  • Forrow, Stephen
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Trinité, Benjamin
  • Blanco, Julià
Animal models have been instrumental in elucidating the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and in testing coronavirus disease 2019 (COVID-19) vaccines and therapeutics. Wild-type (WT) mice are not susceptible to many SARS-CoV-2 variants, and therefore, transgenic K18-hACE2 mice have emerged as a standard model system. However, this model is characterized by a severe disease, particularly associated with neuroinfection, which leads to early humane endpoint euthanasia. Here, we established a novel knock-in (KI) mouse model by inserting the original K18-hACE2 transgene into the collagen type I alpha chain (COL1A1) locus using a recombinase-mediated cassette exchange (RMCE) system. Once the Col1a1-K18-hACE2 mouse colony was established, animals were challenged with a B.1 SARS-CoV-2 (D614G) isolate and were monitored for up to 14 days. Col1a1-K18-hACE2 mice exhibited an initial weight loss similar to the K18-hACE2 transgenic model but did not develop evident neurologic clinical signs. The majority of Col1a1-K18-hACE2 mice did not reach the pre-established humane endpoint, showing a progressive weight gain 9 days postinfection (dpi). Importantly, despite this apparent milder pathogenicity of the virus in this mouse model compared to the K18-hACE2 transgenic model, high levels of viral RNA were detected in the lungs, oropharyngeal swab, and nasal turbinates. Moreover, the remaining lesions and inflammation in the lungs were still observed 14 dpi. In contrast, although low-level viral RNA could be detected in a minority of Col1a1-K18-hACE2 animals, no brain lesions were observed at any timepoint. Overall, Col1a1-K18-hACE2 mice constitute a new model for investigating SARS-CoV-2 pathogenesis and treatments, with potential implications for studying long-term COVID-19 sequelae., The authors would like to acknowledge Jorge Díaz, Yaiza Rosales-Salgado, Rosa María Ampudia-Carrasco, Sergi Sunyé-Casas, and Mireia Martínez from the CMCiB for their essential help in the BSL3 facility and the K18-hACE2 mouse colony. We also thank Marisa Larramona from Parc Científic de Barcelona for her invaluable help with the knock-in mouse colony. We thank the Dormeur Fondation for their financial support for the acquisition of the QuantStudio-5 real-time PCR system. A.P.-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698). This study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya 2021 SGR 00452, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00, PID2020-117145RB-I00, and 10.13039/501100011033, Spain), the EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and the institutional funding of Pharma Mar, Grifols, HIPRA, and Amassence. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. A.P.-G., F.T.-F., B. Trinité, and J.B. conceived and designed the experiments. A.P.-G., F.T.-F., and B. Trinité performed the animal procedures. A.P.-G., F.T.-F., M.P., E.R.-M., D.R.-R., D.P.-Z., J.M.-B., E.P., J.S., and B. Trinité performed the analytical experiments. A.P.-G., B. Trinité, J.S., J.V.-A., V.U., and J.B. analyzed and interpreted the data. S.F. and B. Tondelli established and provided the knock-in mouse colony. S.C. established communication between animal facilities and contributed to the veterinary report verification to allow the knock-in animal shipment to the CMCiB facility. D.P.-Z., J.M.-B., D.R.-R., and N.I.-U. provided key reagents. A.P.-G., B. Trinité, and J.B. wrote the paper. All authors contributed to the article and approved the submitted version., info:eu-repo/semantics/publishedVersion
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

  • Muñoz-Basagoiti, Jordana
  • Monteiro, Fábio Luís Lima
  • Krumpe, Lauren R.H.
  • Armario-Nájera, Victoria
  • Shenoy, Shilpa R.
  • Perez-Zsolt, Daniel
  • Westgarth, Harrison James
  • Villorbina Noguera, Gemma
  • Bomfim, Larissa Maciel
  • Raïch-Regué, Dàlia
  • Nogueras Penabad, Lara
  • Henrich, Curtis J.
  • Gallemí, Marçal
  • Moreira, Filipe Romero Rebello
  • Torres Cabestany, Pascual
  • Wilson, Jennifer
  • D’arc, Mirela
  • Marfil, Silvia
  • Herlinger, Alice Laschuk
  • Pradenas, Edwards
  • Higa, Luiza Mendonça
  • Portero Otín, Manuel
  • Trinité, Benjamin
  • Twyman, Richard M.
  • Capell Capell, Teresa
  • Tanuri, Amilcar
  • Blanco, Julià
  • Izquierdo-Useros, Nuria
  • Rech, Elibio L.
  • Christou, Paul
  • O’Keefec, Barry R.
  • Higa, Higa,Luiza Mendonça
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive stranded RNA virus which has caused the recent deadly pandemic called COVID-19. The SARS-CoV-2 virion is coated with a heavily glycosylated Spike glycoprotein which is responsible for attachment and entry into target cells. One, as yet unexploited strategy for preventing SARS-CoV-2 infections, is the targeting of the glycans on Spike. Lectins are carbohydrate-binding proteins produced by plants, algae, and cyanobacteria. Some lectins can neutralize enveloped viruses displaying external glycoproteins, offering an alternative therapeutic approach for the prevention of infection with virulent β-coronaviruses, such as SARS-CoV-2. Here we show that the cyanobacterial lectin cyanovirin-N (CV-N) can selectively target SARS-CoV-2 Spike oligosaccharides and inhibit SARS-CoV-2 infection in vitro and in vivo. CV-N neutralizes Delta and Omicron variants in vitro better than earlier circulating viral variants. CV-N binds selectively to Spike with a Kd as low as 15 nM and a stoichiometry of 2 CV-N: 1 Spike but does not bind to the receptor binding domain (RBD). Further mapping of CV-N binding sites on Spike shows that select high-mannose oligosaccharides in the S1 domain of Spike are targeted by CV-N. CV-N also reduced viral loads in the nares and lungs in vivo to protect hamsters against a lethal viral challenge. In summary, we present an anti-coronavirus agent that works by an unexploited mechanism and prevents infection by a broad range of SARS-CoV-2 strains., Agricultural Biotechnology and Bioeconomy Unit (ABBU), Universitat de Lleida, Spain, EU Pharma-Factory grant agreement 77,4078 to P.C. Research in NI-U’s lab is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00),EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols,Pharma Mar,HIPRA,Amassence,and Palobiofarma. E.L.R. is supported by Embrapa Genetic Resources and Biotechnology/National Institute of Science and Technology in Synthetic Biology, National Council for Scientific and Technological Development (465603/2014-9), Research Support Foundation of the Federal District (0193.001.262/2017), and Coordination for the Improvement of Higher Education Personnel. This research has been supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research and with federal funds from the NCI, NIH, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S.Government.All animal experiments were approved by
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dàlia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Perez-Zsolt, Daniel
  • Muñoz-Basagoiti, Jordana
  • Sachse, Martín
  • Fernández-Sánchez, Sara Yolanda
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Núñez-Delicado, Estrella
  • Casas, Josefina
  • Tarrés-Freixas, Ferrán
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Núria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that we count with few coronavirus-fighting drugs. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety and tolerability profiles. We began elaborating a list of 116 drugs previously used to treat other pathologies or characterized in pre-clinical studies with potential to treat coronavirus infections. We next employed molecular modelling tools to rank the 44 most promising inhibitors and tested their efficacy as antivirals against a panel of alpha and beta coronavirus, e.g., the HCoV-229E and SARS-CoV-2 viruses. Four drugs, OSW-1, U18666A, hydroxypropyl-beta-cyclodextrin (HbetaCD) and phytol, showed antiviral activity against both HCoV-229E (in MRC5 cells) and SARS-CoV-2 (in Vero E6 cells). The mechanism of action of these compounds was studied by transmission electron microscopy (TEM) and by testing their capacity to inhibit the entry of SARS-CoV-2 pseudoviruses in ACE2-expressing HEK-293T cells. The entry was inhibited by HbetaCD and U18666A, yet only HbetaCD could inhibit SARS-CoV-2 replication in the pulmonary cells Calu-3. With these results and given that cyclodextrins are widely used for drug encapsulation and can be safely administered to humans, we further tested 6 native and modified cyclodextrins, which confirmed β-cyclodextrins as the most potent inhibitors of SARS-CoV-2 replication in Calu-3 cells. All accumulated data points to beta-cyclodextrins as promising candidates to be used in the therapeutic treatments for SARS-CoV-2 and possibly other respiratory viruses., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2,916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Highly Efficient Air Sterilization via Low-Temperature Interfacial Evaporation in Inductively Heated Superhydrophilic Ferromagnetic Filters

  • Fons, Arnau
  • Vaca, Cristina
  • Franco-Trepat, Eloi
  • Lafuente, Aritz
  • Tajada Herráiz, José Luis
  • Serrà, Albert
  • Díaz Pedroza, Jorge
  • Franco, Sandra
  • Boreika, Rytis
  • Erkizia, Itziar
  • Izquierdo-Useros, Núria
  • López-Ortega, Alberto
  • Garaio, Eneko
  • Esplandiú, María J.
  • Nogués, Josep
  • Sepúlveda, Borja
The scientific evidence supporting airborne transmission of pathogens in closed spaces highlights the inefficiency of current air circulation and filtration technologies (e.g., HEPA filters, UV, ozone, ionization) in preventing the spread of airborne pathogens. This underscores the urgent need for new air disinfection devices. Here, the first air sterilization technology is presented based on low-temperature interfacial evaporation. This novel approach integrates superhydrophilic micro/nano-structured stainless-steel filters and ultra-efficient magnetic inductive heating to enable complete evaporation of water from the contaminated aerosols and the precipitation of all the organic and inorganic residues within the filter at temperatures in the range of 60-80 °C. The technology is validated through experiments with contaminated aerosols with different active viruses, including SARS-CoV-2 and respiratory syncytial virus (RSV), demonstrating the elimination of 99.6% or more of the nebulized viruses, at filter temperatures of 60-80 °C and airflow rates of 15 L min-1. The filters also support pyrolytic self-cleaning and reuse, ensuring extended service time and minimal maintenance. This air sterilization technology represents a significant advancement over existing state-of-the-art filtering technology, offering unmatched versatility, low energy consumption, and cost-effective sterilization, without generating harmful radicals, dangerous high voltages, or high temperatures., A.F., C.V., and E.F.-T. contributed equally to this work. Ministerio de Ciencia e Innovación (MICIN) is acknowledged through Grant PDC2021-121303-I00, funded by NextGenerationEU and MICIU/AEI/10.13039/501100011033. MICIN is also acknowledged through Grants PID2021-124568NB-I00, PDI2022-138588OB-C31 and PDI2022-138588OB-C32 funded by MICIU/AEI/10.13039/501100011033. The IMB is supported by the Maria de Maeztu Centres of Excellence program Grant CEX2023-001397-M and the ICN2 is supported by the Severo Ochoa Centres of Excellence program, Grant CEX2021-001214-S, both funded by MCIU/AEI/10.13039/501100011033. ICN2 is funded by the CERCA program/Generalitat de Catalunya. The authors acknowledge the funding from 2021-SGR-00651 project by the Generalitat de Catalunya. N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/ 501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. The authors also thank the support of 2021 SGR 00452, CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023-050389-I and A.L.O. by CNS2022-135787 funded by MCIU/AEI/10.13039/ 501100011033, European Union NextGenerationEUPRTR and FSE+, With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (CEX2023-001397-M), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor

  • Jimeno, Jose
  • Varona, Jose Felipe
  • Lopez-Martin, Jose A
  • Izquierdo-Useros, Nuria
  • Molina Molina, Elisa
  • Guisado-Vasco, Pablo
  • Sachse, Martin
  • Risco, Cristina
  • Losada, Alejandro
  • Fudio, Salvador
  • Luepke, Erik
  • Nieto, Antonio
  • Gomez, Javier
  • Aviles, Pablo
  • Cuevas, Carmen
  • Bouhaddou, Mehdi
  • Solá Gurpegui, Isabel
  • Krogan, Nevan J
  • Enjuanes Sánchez, Luis
  • Fernandez-Sousa, Jose M
  • GarcÍa-Sastre, Adolfo
  • White, Kris
Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis., The studies described in this manuscript were primarily funded by PharmaMar, which supported the preclinical development, mechanistic studies, and clinical trials of plitidepsin in cancer and SARS-CoV-2 infection. This includes work contributed by AL, PA, CC, SF, EL, AN, JG, CR, MS, IS, LE, JFV, PGV, JALM, and JJ. NI-U was supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00, and 10.13039/501100011033), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118), HORIZON-HLTH-2023-DISEASE-03, 2021 SGR 00452 (Generalitat de Catalunya/CERCA programme), and institutional funding from PharmaMar, Grifols, HIPRA, and Amassence. EM-M was supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). Medical writing support by Timothy Silverstein, PhD (Feather Medical Communications), was funded by PharmaMar. A.G.-S. and N.J.K. acknowledge research support from the National Institutes of Health (NIH) through R01AI137200 and R01AI153356. A.G.-S. also acknowledges support from R01AI163011, R35GM137905, R01HL169500, and the Mount Sinai Dean's Fund for COVID-19 Research. N.J.K. also acknowledges institutional support from the Gladstone Institutes and the Roddenberry Foundation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain

  • Agustí Benito, Cristina
  • Adell Lorente, Héctor
  • Casabona, Jordi
The recent monkeypox virus (MPXV) outbreak was of global concern and has mainly affected gay, bisexual and other men who have sex with men (GBMSM). Here we assess prevalence of MPXV in high-risk populations of GBMSM, trans women (TW) and non-binary people without symptoms or with unrecognized monkeypox (Mpox) symptoms, using a self-sampling strategy. Anal and pharyngeal swabs are tested by MPXV real-time PCR and positive samples are tested for cytopathic effect (CPE) in cell culture. 113 individuals participated in the study, 89 (78.76%) were cis men, 17 (15.04%) were TW. The median age was 35.0 years (IQR: 30.0–43.0), 96 (85.02%) individuals were gay or bisexual and 72 (63.72%) were migrants. Seven participants were MPXV positive (6.19% (95% CI: 1.75%–10.64%)). Five tested positive in pharyngeal swabs, one in anal swab and one in both. Six did not present symptoms recognized as MPXV infection. Three samples were positive for CPE, and showed anti-vaccinia pAb staining by FACS and confocal microscopy. This suggests that unrecognized Mpox cases can shed infectious virus. Restricting testing to individuals reporting Mpox symptoms may not be sufficient to contain outbreaks., The authors acknowledge the collaboration of Gema Ballega, Pili Bonamusa, Pamela Nef, Ana Isabel Parra Manzano, Enola Crespillo, Aroa Muñoz, Núria Vaquero, Elisa Molina Molina and F. Hoffmann-La Roche Ltd. In addition, the authors thank Harvey Evans for the English revision. This work was supported by the Ministry of Health of Government of Catalonia (Spain) [no grant number] and Hoffmann-La Roche Laboratories. NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding from Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. Finally, the authors thank the CERCA Programme/Generalitat de Catalunya for their support of the Germans Trias i Pujol Research Institute (IGTP).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna
  • Tarrés Freixas, Ferran
  • Pérez Maíllo, Mónica
  • Riveira-Muñoz, Eva
  • Raïch-Regué, Dàlia
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Tondelli, Barbara
  • Pradenas, Edwards
  • Izquierdo-Useros, Nuria
  • Capdevila, Sara
  • Vergara-Alert, Júlia
  • Urrea, Victor
  • Carrillo, Jorge
  • Ballana, Ester
  • Forrow, Stephen
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Trinité, Benjamin
  • Blanco, Julià
Animal models have been instrumental in elucidating the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and in testing coronavirus disease 2019 (COVID-19) vaccines and therapeutics. Wild-type (WT) mice are not susceptible to many SARS-CoV-2 variants, and therefore, transgenic K18-hACE2 mice have emerged as a standard model system. However, this model is characterized by a severe disease, particularly associated with neuroinfection, which leads to early humane endpoint euthanasia. Here, we established a novel knock-in (KI) mouse model by inserting the original K18-hACE2 transgene into the collagen type I alpha chain (COL1A1) locus using a recombinase-mediated cassette exchange (RMCE) system. Once the Col1a1-K18-hACE2 mouse colony was established, animals were challenged with a B.1 SARS-CoV-2 (D614G) isolate and were monitored for up to 14 days. Col1a1-K18-hACE2 mice exhibited an initial weight loss similar to the K18-hACE2 transgenic model but did not develop evident neurologic clinical signs. The majority of Col1a1-K18-hACE2 mice did not reach the pre-established humane endpoint, showing a progressive weight gain 9 days postinfection (dpi). Importantly, despite this apparent milder pathogenicity of the virus in this mouse model compared to the K18-hACE2 transgenic model, high levels of viral RNA were detected in the lungs, oropharyngeal swab, and nasal turbinates. Moreover, the remaining lesions and inflammation in the lungs were still observed 14 dpi. In contrast, although low-level viral RNA could be detected in a minority of Col1a1-K18-hACE2 animals, no brain lesions were observed at any timepoint. Overall, Col1a1-K18-hACE2 mice constitute a new model for investigating SARS-CoV-2 pathogenesis and treatments, with potential implications for studying long-term COVID-19 sequelae., The authors would like to acknowledge Jorge Díaz, Yaiza Rosales-Salgado, Rosa María Ampudia-Carrasco, Sergi Sunyé-Casas, and Mireia Martínez from the CMCiB for their essential help in the BSL3 facility and the K18-hACE2 mouse colony. We also thank Marisa Larramona from Parc Científic de Barcelona for her invaluable help with the knock-in mouse colony. We thank the Dormeur Fondation for their financial support for the acquisition of the QuantStudio-5 real-time PCR system. A.P.-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698). This study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya 2021 SGR 00452, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00, PID2020-117145RB-I00, and 10.13039/501100011033, Spain), the EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and the institutional funding of Pharma Mar, Grifols, HIPRA, and Amassence. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. A.P.-G., F.T.-F., B. Trinité, and J.B. conceived and designed the experiments. A.P.-G., F.T.-F., and B. Trinité performed the animal procedures. A.P.-G., F.T.-F., M.P., E.R.-M., D.R.-R., D.P.-Z., J.M.-B., E.P., J.S., and B. Trinité performed the analytical experiments. A.P.-G., B. Trinité, J.S., J.V.-A., V.U., and J.B. analyzed and interpreted the data. S.F. and B. Tondelli established and provided the knock-in mouse colony. S.C. established communication between animal facilities and contributed to the veterinary report verification to allow the knock-in animal shipment to the CMCiB facility. D.P.-Z., J.M.-B., D.R.-R., and N.I.-U. provided key reagents. A.P.-G., B. Trinité, and J.B. wrote the paper. All authors contributed to the article and approved the submitted version., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta
  • Du, Juan
  • Wortmann, Diana D. J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza
  • Arrieta Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier
  • Grau Cerrato, Santiago
  • Garcia Giralt, Natàlia
  • Perez-Zsolt, Daniel
  • Boreika, Rytis
  • Izquierdo-Useros, Nuria
  • Güerri Fernández, Roberto
  • Meyerhans, Andreas
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations., This work received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), Centro de Investigación Biomédica en Red Enfermedades Infecciosas, CIBERINFEC (CB21/13/00002), FEDER funds, FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, the Spanish Ministry of Science and Innovation grant number PID2022-141395OB-I00, and the “Unidad de Excelencia María de Maeztu,” funded by the MCIN and the AEI (DOI: 10.13039/501100011033). Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection

  • Raïch-Regué, Dalia
  • Tenorio, Raquel
  • Fernández de Castro, Isabel
  • Tarrés Freixas, Ferran
  • Sachse, Martin
  • Perez-Zsol, Daniel
  • Muñoz Basagoiti, Jordana
  • Fernández-Sánchez, Sara Y.
  • Gallemí, Marçal
  • Ortega-González, Paula
  • Fernández-Oliva, Alberto
  • Gabaldón, José A.
  • Nuñez-Delicado, Estrella
  • Casas, Josefina
  • Roca, Núria
  • Cantero, Guillermo
  • Pérez, Mónica
  • Usai, Carla
  • Lorca-Oró, Cristina
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Blanco, Julià
  • Clotet Sala, Bonaventura
  • Cerón-Carrasco, José P.
  • Izquierdo-Useros, Nuria
  • Risco, Cristina
The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals., This work has been funded by grant RTI2018-094445-B100 (MCIU/AEI/FEDER, UE) from the Ministry of Science and Innovation of Spain (C.R.), by Palex Medical S.A., Sika S.A.U. and 7 more companies, and by Ms. Raquel Casaus Alvarez, Mr. Miguel Pardo Gil, Mr. Jacques Noguès and a total of 2916 citizens through the Precipita crowdfunding platform of Fecyt (Fundación Española para la Ciencia y la Tecnología). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols, Pharma Mar, HIPRA, Amassence and Palobiofarma. This work used the computational resources of the Centro de Supercomputación de Galicia (CESGA) supported by the Partnership for Advanced Computing in Europe (PRACE) COVID-19 Fast Track Call for Proposals – Allocation Decision – Proposal COVID19-85., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species

  • Tarrés Freixas, Ferran
  • Ceada, Gerardo
  • Català-Moll, Francesc
  • Casadellà, Maria
  • Tolosa-Alarcón, Sara
  • Franco-Trepat, Eloi
  • Boreika, Rytis
  • Almagro-Delgado, Vanessa
  • Carmona, Noelia
  • Estruch, Josep
  • Fernández-Bellon, Hugo
  • Fuentes-Moyano, Laura
  • Molina-López, Rafael
  • Navarro, Nuria
  • Parera, Mariona
  • Pérez Simó, Marta
  • Repullés, Joan
  • Roca, Núria
  • Torne, Odalys
  • Velarde, Roser
  • Valencia, Alfonso
  • Paredes, Roger
  • Izquierdo-Useros, Nuria
  • Romero-Durana, Miguel
  • Kochanowski, Karl
  • Vergara-Alert, Júlia
Identifying animal species that are susceptible to the plethora of existing and emerging viruses is critical for predicting and containing disease outbreaks. Current efforts to assess viral tropism largely rely on experimental infection models, but such experiments are logistically and ethically infeasible for many wildlife species. To tackle this challenge, we developed a panel of airway organoids from ten taxonomically diverse wildlife and livestock species and evaluated their susceptibility to influenza viruses of mammalian (pH1N1) and avian (H5N1) origin. Our analyses revealed large host-specific differences in infection rate and cytopathogenicity that aligned with known in vivo data and field observations. Furthermore, we demonstrated that this organoid panel can serve as a powerful tool to elucidate receptor-binding mechanisms, viral dynamics and early host adaptation in poorly characterized animal hosts. In summary, this work provides a robust and ethically viable approach for evaluating viral tropism and adaptation in wildlife species, and may aid current pandemic preparedness, zoonotic disease surveillance and wildlife conservation efforts., This project was supported by a “Proyectos en lineas estratégicas” grant from the Spanish Ministry of Research and Innovation (project ID: PLEC2022-009171 /AEI/10.13039/501100011033). KK acknowledges additional support by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033). N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 /AEI/10.13039/501100011033), EU HORIZON-HLTH-2021 CORONA-01 (grant 101046118), EU HORIZON-HLTH-2023-DISEASE-03, and by institutional funding from PharmaMar, HIPRA, Amassence and Smart Vitamins. NIU is part of PTI-CSIC Salud Global. The authors also thank the support of CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023050389-I. MRD was supported by a fellowship within the “Generación D” initiative, Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by the European Union NextGenerationEU funds through PRTR. The authors also acknowledge the crowdfunding initiative #Yomecorono, available online at https://www.yomecorono.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals

  • Usai, Carla
  • Pailler García, Lola
  • Lorca-Oró, Cristina
  • Fernández-Bastit, Leira
  • Roca, Núria
  • Brustolin, Marco
  • Rodon Aldrufeu, Jordi
  • Pérez, Mónica
  • Cantero Portillo, Guillermo
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Clotet, Bonaventura
  • Napp, Sebastian
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
Rodents are widely used for the development of COVID-19-like animal models, the virological outcome being determined through several laboratory methods reported in the literature. Our objective was to assess the agreement between methods performed on different sample types from 342 rodents experimentally infected with SARS-CoV-2 (289 golden Syrian hamsters and 53 K18-hACE2 mice). Our results showed moderate agreement between methods detecting active viral replication, and that increasing viral loads determined by either RT-qPCR or infectious viral titration corresponded to increasing immunohistochemical scores. The percentage of agreement between methods decreased over experimental time points, and we observed poor agreement between RT-qPCR results and viral titration from oropharyngeal swabs. In conclusion, RT-qPCR and viral titration on tissue homogenates are the most reliable techniques to determine the presence and replication of SARS-CoV-2 in the early and peak phases of infection, and immunohistochemistry is valuable to evaluate viral distribution patterns in the infected tissues., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

  • Muñoz-Basagoiti, Jordana
  • Monteiro, Fábio Luís Lima
  • Krumpe, Lauren R.H.
  • Armario-Nájera, Victoria
  • Shenoy, Shilpa R.
  • Perez-Zsolt, Daniel
  • Westgarth, Harrison James
  • Villorbina Noguera, Gemma
  • Bomfim, Larissa Maciel
  • Raïch-Regué, Dàlia
  • Nogueras Penabad, Lara
  • Henrich, Curtis J.
  • Gallemí, Marçal
  • Moreira, Filipe Romero Rebello
  • Torres Cabestany, Pascual
  • Wilson, Jennifer
  • D’arc, Mirela
  • Marfil, Silvia
  • Herlinger, Alice Laschuk
  • Pradenas, Edwards
  • Higa, Luiza Mendonça
  • Portero Otín, Manuel
  • Trinité, Benjamin
  • Twyman, Richard M.
  • Capell Capell, Teresa
  • Tanuri, Amilcar
  • Blanco, Julià
  • Izquierdo-Useros, Nuria
  • Rech, Elibio L.
  • Christou, Paul
  • O’Keefec, Barry R.
  • Higa, Higa,Luiza Mendonça
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive stranded RNA virus which has caused the recent deadly pandemic called COVID-19. The SARS-CoV-2 virion is coated with a heavily glycosylated Spike glycoprotein which is responsible for attachment and entry into target cells. One, as yet unexploited strategy for preventing SARS-CoV-2 infections, is the targeting of the glycans on Spike. Lectins are carbohydrate-binding proteins produced by plants, algae, and cyanobacteria. Some lectins can neutralize enveloped viruses displaying external glycoproteins, offering an alternative therapeutic approach for the prevention of infection with virulent β-coronaviruses, such as SARS-CoV-2. Here we show that the cyanobacterial lectin cyanovirin-N (CV-N) can selectively target SARS-CoV-2 Spike oligosaccharides and inhibit SARS-CoV-2 infection in vitro and in vivo. CV-N neutralizes Delta and Omicron variants in vitro better than earlier circulating viral variants. CV-N binds selectively to Spike with a Kd as low as 15 nM and a stoichiometry of 2 CV-N: 1 Spike but does not bind to the receptor binding domain (RBD). Further mapping of CV-N binding sites on Spike shows that select high-mannose oligosaccharides in the S1 domain of Spike are targeted by CV-N. CV-N also reduced viral loads in the nares and lungs in vivo to protect hamsters against a lethal viral challenge. In summary, we present an anti-coronavirus agent that works by an unexploited mechanism and prevents infection by a broad range of SARS-CoV-2 strains., Agricultural Biotechnology and Bioeconomy Unit (ABBU), Universitat de Lleida, Spain, EU Pharma-Factory grant agreement 77,4078 to P.C. Research in NI-U’s lab is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00),EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols,Pharma Mar,HIPRA,Amassence,and Palobiofarma. E.L.R. is supported by Embrapa Genetic Resources and Biotechnology/National Institute of Science and Technology in Synthetic Biology, National Council for Scientific and Technological Development (465603/2014-9), Research Support Foundation of the Federal District (0193.001.262/2017), and Coordination for the Improvement of Higher Education Personnel. This research has been supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research and with federal funds from the NCI, NIH, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S.Government.All animal experiments were approved by
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • de Homdedeu, Miquel
  • Sanchez-Moral, Lidia
  • Violán, Concepció
  • Ràfols, Neus
  • Ouchi, Dan
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodríguez-Cortés, Alhelí
  • Arch-Sisquella, Marta
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Izquierdo-Useros, Nuria
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi
  • Segalés, Joaquim
  • Vilaplana, Cristina
  • Torán-Monserrat, Pere
  • Morros, Rosa
  • Monfà, Ramon
  • Sarrias, Maria-Rosa
  • Cardona, Pere-Joan
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days., The MANRECOVID19 clinical trial has been sponsored by the Reig Jofre Group. This research was funded by the Consorcio Centro de Investigación Biomédica en Red (CIBERES and CIBEREHD) and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847762. MDH is supported by a Margarita Salas grant from NextGenerationEU. LS-M is supported by Juan de la Cierva fellowship (FJC2019-041213-I). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118), and institutional funding from Grifols, Pharma Mar, HIPRA, Amassence, and Palobiofarma. The Innate Immunity lab and the UTE are accredited by the Catalan Agency for Management of University and Research Grants (2017-SGR-490/2021-SGR-01186, 2021-SGR-00931, and 2017-SGR-500/2021 SGR 00920). IGTP is a member of the CERCA network of institutes supported by the Health Department of the Government of Catalonia., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals

  • Usai, Carla|||0000-0002-6373-2765
  • Pailler-García, Lola|||0000-0003-1211-7057
  • Lorca-Oró, Cristina|||0000-0001-5351-4169
  • Fernández-Bastit, Leira|||0000-0002-7766-939X
  • Roca, Núria
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodon, Jordi|||0000-0002-1032-9091
  • Pérez, Mónica
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Napp Avelli, Sebastián|||0000-0001-5813-7286
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
Rodents are widely used for the development of COVID-19-like animal models, the virological outcome being determined through several laboratory methods reported in the literature. Our objective was to assess the agreement between methods performed on different sample types from 342 rodents experimentally infected with SARS-CoV-2 (289 golden Syrian hamsters and 53 K18-hACE2 mice). Our results showed moderate agreement between methods detecting active viral replication, and that increasing viral loads determined by either RT-qPCR or infectious viral titration corresponded to increasing immunohistochemical scores. The percentage of agreement between methods decreased over experimental time points, and we observed poor agreement between RT-qPCR results and viral titration from oropharyngeal swabs. In conclusion, RT-qPCR and viral titration on tissue homogenates are the most reliable techniques to determine the presence and replication of SARS-CoV-2 in the early and peak phases of infection, and immunohistochemistry is valuable to evaluate viral distribution patterns in the infected tissues.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • Homdedeu, Miquel de|||0000-0002-2865-1740
  • Sanchez-Moral, Lidia|||0000-0002-3795-8015
  • Violán, Concepció|||0000-0003-3309-5360
  • Ràfols, Neus
  • Ouchi, Dan|||0000-0002-8630-152X
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodriguez-Cortes, Alheli|||0000-0003-3617-0119
  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi|||0000-0002-0968-7713
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Morros, Rosa|||0000-0001-6752-8748
  • Monfà, Ramon|||0000-0002-1324-3971
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days. Biological sciences; Molecular biology; Immunology; Microbiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Guallar, Victor|||0000-0002-4580-1114
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta|||0000-0003-0214-6348
  • Du, Juan
  • Wortmann, Diana D.J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza|||0000-0002-4651-7545
  • Arrieta-Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier|||0000-0002-2528-0382
  • Grau, Santiago|||0000-0002-8428-1836
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Boreika, Rytis|||0000-0001-6720-1577
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Meyerhans, Andreas|||0000-0003-0620-5317
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Highly efficient air sterilization via low-temperature interfacial evaporation in inductively heated superhydrophilic ferromagnetic filters

  • Fons, Arnau
  • Blanco Vaca, Cristina
  • Franco Trepat, Eloi
  • Lafuente, Aritz
  • Tajada, José Luis
  • Serrá, Albert
  • Díaz Pedroza, Jorge
  • Franco, Sandra
  • Boreika, Rytis
  • Erkizia, Itziar
  • Izquierdo-Useros, Nuria
  • López Ortega, Alberto
  • Garayo Urabayen, Eneko
  • Esplandiu, Maria José
  • Nogués, Josep
  • Sepúlveda, Borja
The scientific evidence supporting airborne transmission of pathogens in closed spaces highlights the inefficiency of current air circulation and filtration technologies (e.g., HEPA filters, UV, ozone, ionization) in preventing the spread of airborne pathogens. This underscores the urgent need for new air disinfection devices. Here, the first air sterilization technology is presented based on low-temperature interfacial evaporation. This novel approach integrates superhydrophilic micro/nano-structured stainless-steel filters and ultra-efficient magnetic inductive heating to enable complete evaporation of water from the contaminated aerosols and the precipitation of all the organic and inorganic residues within the filter at temperatures in the range of 60–80 °C. The technology is validated through experiments with contaminated aerosols with different active viruses, including SARS-CoV-2 and respiratory syncytial virus (RSV), demonstrating the elimination of 99.6% or more of the nebulized viruses, at filter temperatures of 60–80 °C and airflow rates of 15 L min−1. The filters also support pyrolytic self-cleaning and reuse, ensuring extended service time and minimal maintenance. This air sterilization technology represents a significant advancement over existing state-of-the-art filtering technology, offering unmatched versatility, low energy consumption, and cost-effective sterilization, without generating harmful radicals, dangerous high voltages, or high temperatures., Ministerio de Ciencia e Innovación (MICIN) is acknowledged through Grant PDC2021-121303-I00, funded by NextGenerationEU and MICIU/AEI/10.13039/501100011033. MICIN is also acknowledged through Grants PID2021-124568NB-I00, PDI2022-138588OB-C31 and PDI2022-138588OB-C32 funded by MICIU/AEI/10.13039/501100011033. The IMB is supported by the Maria de Maeztu Centres of Excellence program Grant CEX2023-001397-M and the ICN2 is supported by the Severo Ochoa Centres of Excellence program, Grant CEX2021-001214-S, both funded by MCIU/AEI/10.13039/501100011033. ICN2 is funded by the CERCA program/Generalitat de Catalunya. The authors acknowledge the funding from 2021-SGR-00651 project by the Generalitat de Catalunya. N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/ 501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. The authors also thank the support of 2021 SGR 00452, CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023-050389-I and A.L.O. by CNS2022-135787 funded by MCIU/AEI/10.13039/ 501100011033, European Union NextGenerationEUPRTR and FSE+.